Targeting tumor elicitedimmunosuppressive pathways has proven to be an efficient means of boosting antitumor immunity. The potential of this approach is underlined by the clinical success of monoclonal antibodies targeting cytotoxic T lymphocyte-associated protein 4 (CTLA4), programmed cell death 1 (PDCD1, best known as PD-1) and CD274 (best known as PD-L1). 1 One of the immunosuppressive pathways that has largely been overlooked relies on the generation of adenosine by 5'-nucleotidase, ecto (NT5E, best known as CD73). The expression of this ectoenzyme enhances tumor progression and metastatic dissemination. In line with this notion, the expression of CD73 is a poor prognostic marker among triple negative breast cancer patients. [2] [3] [4] The activation of both A 2A and A 2B adenosine receptors has been shown to suppress antitumor T-cell responses within the tumor microenvironment. 3, 5, 6 However, the mechanisms by which CD73 promotes metastasis were less clear. Therefore, we recently set out to investigate the molecular and cellular cascades that underlie the prometastatic activity of CD73. 7 We first investigated whether ectopic CD73 expression is sufficient to increase the metastatic potential of CD73 − tumors.
We chose AT-3 breast carcinoma and B16F10 melanoma cells since they constitute a weakly metastatic and a highly metastatic tumor model, respectively. In both settings, CD73 expression significantly enhanced tumor metastasis. Although the major biological function of CD73 is the generation of adenosine, this ectoenzyme has been attributed with additional roles. 8 Therefore, we investigated whether exogenous adenosine could mimic the prometastatic effects of CD73. The pre-treatment of mice with 5'(N-ethylcarboxamido) adenosine (NECA), a stable analog of adenosine that operates as a pan-agonist for A 1 Although our data show an unequivocal role for A 2A -mediated immunosuppression in the pro-metastatic effect of CD73, this is not the only mechanism whereby CD73 stimulates tumor metastasis. Indeed, we found that CD73 expression promotes the metastatic dissemination of tumor cells in immunocompromised mice, indicating that CD73 also exerts tumorpromoting effects via non-immunological mechanisms. Notably, the autoactivation of A 2B receptors on neoplastic cells has previously been shown to enhance their invasive potential by stimulating the formation of filopodia. 3, 9 Intriguingly, it has recently been shown that CD73 can promote the metastatic dissemination of tumor cells in vivo independently of its catalytic activity, indicating that the activation of adenosine receptors may not fully account for the pro-metastatic effects of CD73. 10 In summary, our data indicate that CD73 favors tumor metastasis by multiple mechanisms including the generation of adenosine, and activation of A 2A receptors of the host (Fig. 1) . Our data clearly suggest that the blockade of A 2A or A 2B represents a potential therapeutic strategy to limit metastasis. As antagonists of these receptors are already under clinical development for other indications and show good safety profiles, the translation of our findings to cancer patients appears feasible. 
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